Literature DB >> 6207992

Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids.

D A White, D E Stover.   

Abstract

Ten (3 percent) of 287 patients receiving combination chemotherapy developed severe bleomycin-induced pneumonitis. The course and the response to therapy in these patients are summarized in this report. The dose of bleomycin received varied from 136 to 588 units, with toxic effects occurring in six patients who had received less than 200 units. Dyspnea and dry cough were the presenting symptoms in nine patients; one was asymptomatic. Roentgenograms were abnormal in nine cases, with five showing bilateral infiltrates. Four patients had asymmetric abnormalities, with radiographic involvement of only a single lung in two of these. Pulmonary function tests were abnormal, with a decreased diffusing capacity. Seven patients were treated with corticosteroid therapy, and significant clinical and radiographic improvement was noted; however, pulmonary function tests remained abnormal and could not be used to monitor the response. Prolonged therapy with corticosteroids was required over many months to maintain improvement. Tapering of the steroid dosage led to recurrence of clinical symptoms and radiographic infiltrates in five patients. Mortality was 60 percent, with three early deaths in untreated patients and three late deaths which occurred 12 to 15 months after diagnosis. In this study, patients with severe bleomycin-induced pneumonitis had symptomatic improvement and roentgenographic clearing following corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207992     DOI: 10.1378/chest.86.5.723

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

Review 1.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

2.  Fatal pneumothorax associated with bleomycin-induced pulmonary fibrosis.

Authors:  D C Doll
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Authors:  J G Hay; P L Haslam; A Dewar; B Addis; M Turner-Warwick; G J Laurent
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

Review 4.  Interstitial lung disease: progress and problems.

Authors:  S J Bourke
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

5.  Imatinib Treatment for Bleomycin-Induced Pulmonary Toxicity.

Authors:  Nilüfer Aykaç; Coşkun Tecimer
Journal:  Turk Thorac J       Date:  2020-11-01

6.  Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.

Authors:  Martha W den Hollander; Nico-Derk L Westerink; Sjoukje Lubberts; Alfons H H Bongaerts; Rienhart F E Wolf; Renska Altena; Janine Nuver; Sjoukje F Oosting; Elisabeth G E de Vries; Anna M E Walenkamp; Coby Meijer; Jourik A Gietema
Journal:  Oncologist       Date:  2016-06-21

7.  Risk factors for acute respiratory distress syndrome during neutropenia recovery in patients with hematologic malignancies.

Authors:  Chin Kook Rhee; Ji Young Kang; Yong Hyun Kim; Jin Woo Kim; Hyung Kyu Yoon; Seok Chan Kim; Soon Suk Kwon; Young Kyoon Kim; Kwan Hyung Kim; Hwa Sik Moon; Sung Hak Park; Hee Je Kim; Seok Lee; Jeong Sup Song
Journal:  Crit Care       Date:  2009-11-03       Impact factor: 9.097

Review 8.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Postoperative pulmonary complications in patients with esophageal cancer.

Authors:  J Scholz; U Steinhöfel; M Dürig; A Prause; H W Bause; K Hamper; J Schulte am Esch
Journal:  Clin Investig       Date:  1993-04

Review 10.  Diagnosis and management of drug-associated interstitial lung disease.

Authors:  N L Müller; D A White; H Jiang; A Gemma
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.